Arthneeti
Latest: Sigachi Industries Ltd Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
S

Sigachi Industries Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Sigachi Industries Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹34
Market cap₹995 Cr
P/E30.6
Updated26 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

4 of 4 strong

RevenueGood growth
MarginMargins up
CapexCapex planned
FundraiseFundraise planned

The short version

Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter. Revenue guidance for FY27 remains at INR650-675 crores, with quarter-on-quarter improvement expected.

From Sigachi Industries Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Good growth
  • Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter.
  • Full-year revenue guidance remains INR650-675 crores, with expectations to reach INR160-170 crores in quarterly run rate by Q4 FY27.
  • Capacity expansion underway with debottlenecking and adding equipment to increase volumes beyond current 18,000 MT.
  • New capacities with Dahej 2 and CCS facility expected by FY28 to further increase volumes.
  • API segment revenues expected to ramp up from INR21 crores in Q1 to higher levels in subsequent quarters through new high-margin products.
  • Product mix improvements with co-processed excipients and differentiated products to enhance revenue and margins.

2 more points from Sigachi Industries Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sigachi Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Ongoing capex for FY27 is around INR 100 crores, with an additional INR 150-200 crores planned for FY28.
  • Capex focuses on increasing capacity through debottlenecking, adding equipment (shifters, blenders), and product mix enhancements, especially in MCC.
  • New capacity expansions include increasing MCC capacity from 18,000 to 30,000 metric tons in upcoming quarters.
  • Dahej 2 plant expansion is progressing, expected operational by Q2 FY28 (delayed from earlier Q1 FY28 expectation).
  • CCS (Continuous Coating System) facility is expected to be fully operational in FY28.
  • Funding for capex may come from internal accruals, borrowings (bank finance/term loans), and potential preferential equity issuance.

2 more points from Sigachi Industries Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sigachi Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Sigachi Industries is currently receiving orders for the supply of CCS (Co-Processed Superdisintegrants) from export customers, even before the CCS production capacity is operational.
  • Inquiries are coming from foreign customers, likely due to market shortages and existing customer requirements for CCS alongside MCC.
  • The company expects more orders from exports once the CCS facility is operational (planned for FY28).
  • Strong demand is indicated by inquiries and order interest despite current capacity bottlenecks.

Sigachi Industries Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹113 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Sigachi Indust.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sigachi Industries Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sigachi Industries Ltd Q1 FY27 results?

Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter. Revenue guidance for FY27 remains at INR650-675 crores, with quarter-on-quarter improvement expected.

What is Sigachi Industries Ltd share price analysis?

Sigachi Industries Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sigachi Industries Ltd planning capital expenditure?

Ongoing capex for FY27 is around INR 100 crores, with an additional INR 150-200 crores planned for FY28.

Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.